Susquehanna International Group LLP Buys 788,349 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Susquehanna International Group LLP boosted its stake in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 749.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 893,601 shares of the company's stock after purchasing an additional 788,349 shares during the quarter. Susquehanna International Group LLP owned 1.54% of Rezolute worth $4,379,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of RZLT. JPMorgan Chase & Co. acquired a new stake in Rezolute during the third quarter worth $42,000. Charles Schwab Investment Management Inc. boosted its position in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after acquiring an additional 9,000 shares in the last quarter. Virtu Financial LLC increased its stake in Rezolute by 58.0% in the third quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock valued at $126,000 after acquiring an additional 9,551 shares during the period. ExodusPoint Capital Management LP acquired a new position in Rezolute in the fourth quarter worth about $277,000. Finally, Barclays PLC acquired a new position in Rezolute in the fourth quarter worth about $314,000. 82.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Rezolute in a report on Monday, April 28th. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. JMP Securities boosted their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research note on Thursday, February 13th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Rezolute has an average rating of "Buy" and a consensus target price of $26.43.

Insider Activity

In related news, Director Wladimir Hogenhuis bought 10,000 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were purchased at an average price of $4.70 per share, with a total value of $47,000.00. Following the completion of the purchase, the director now owns 77,267 shares of the company's stock, valued at $363,154.90. This represents a 14.87 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Nevan C. Elam bought 12,302 shares of the firm's stock in a transaction dated Thursday, March 27th. The shares were bought at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the transaction, the chief executive officer now directly owns 224,119 shares in the company, valued at approximately $638,739.15. This trade represents a 5.81 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 39,060 shares of company stock valued at $130,694 over the last 90 days. 18.39% of the stock is owned by company insiders.

Rezolute Stock Performance

RZLT traded down $0.03 during midday trading on Friday, hitting $3.69. The company had a trading volume of 520,609 shares, compared to its average volume of 617,823. Rezolute, Inc. has a twelve month low of $2.22 and a twelve month high of $6.19. The company has a market capitalization of $223.37 million, a PE ratio of -3.02 and a beta of 1.01. The firm's 50-day simple moving average is $3.25 and its 200-day simple moving average is $4.37.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.11. As a group, sell-side analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.